Metastatic spread emerging from liver metastases of colorectal cancer does the seed leave the soil again?

Annals of Surgery

Volumn 263, Issue 2, 2016, Pages 345-352

  Rahbari, Nuh N ^a   Bork, Ulrich ^a   Scholch, Sebastian ^a   Reissfelder, Christoph ^a   Thorlund, Kristian ^b   Betzler, Alexander ^a   Kahlert, Christoph ^c   Schneider, Martin ^c   Ulrich, Alexis B ^c   Buchler, Markus W ^c   Weitz, Jurgen ^a   Koch, Moritz ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Circulating tumor cells; Colorectal cancer; Hepatic vein; Liver metastases; Portal vein

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; CELL ADHESION; CELL COUNT; CIRCULATING TUMOR CELL; CIRCULATING TUMOR CELL TEST KIT; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DIAGNOSTIC KIT; FEMALE; GENE EXPRESSION; HEPATIC VENOUS BLOOD; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LIVER VEIN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PORTAL VEIN; PORTAL VEIN BLOOD; PRIORITY JOURNAL; TUMOR CELL; TUMOR VOLUME; VENOUS BLOOD; BLOOD; COLORECTAL TUMOR; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SECONDARY; TUMOR EMBOLISM; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HEPATIC VEINS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASTIC CELLS, CIRCULATING; PORTAL VEIN; PROSPECTIVE STUDIES;

EID: 84955635402     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001341     Document Type: Article

References (53)

1. Sporn MB. The war on cancer. Lancet. 1996;347:1377-1381.
2. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:99-101.
3. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275-292.
4. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139:1315-1326.
5. Comen E, Norton L. Self-seeding in cancer. Recent Results Cancer Res. 2012;195:13-23.
6. Tait CR, Dodwell D, Horgan K. Do metastases metastasize? J Pathol. 2004;203:515-518.
7. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004;4:448-456.
8. Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138:1714-1726.
9. Cohen SJ, Punt CJ, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223-1229.
10. Huo TI, Lui WY, Wu JC, et al. Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors, and association with intrahepatic tumor recurrence. World J Surg. 2004;28: 258-262.
11. Yu M, Ting DT, Stott SL, et al. RNA sequencingofpancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012;487:510-513.
12. Punnoose EA, Atwal SK, Spoerke JM, et al. Molecular biomarker analyses using circulating tumor cells. PLoS One. 2010;5:e12517.
13. Rahbari NN, Bork U, Kircher A, et al. Compartmental differences of circulating tumor cells in colorectal cancer. Ann Surg Oncol. 2012;19:2195-2202.
14. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180-1184.
15. Rahbari NN, Reissfelder C, Muhlbayer M, et al. Correlation of circulating angiogenic factors with circulating tumor cells and disease recurrence in patients undergoing curative resection for colorectal liver metastases. Ann Surg Oncol. 2011;18:2182-2191.
16. Rahbari NN, Koch M, Zimmermann JB, et al. Infrahepatic inferior vena cava clamping for reduction of central venous pressure and blood loss during hepatic resection: a randomized controlled trial. Ann Surg. 2011;253:1102-1110.
17. Rahbari NN, Reissfelder C, Koch M, et al. The predictive value of post-operative clinical risk scores for outcome after hepatic resection: a validation analysis in 807 patients. Ann Surg Oncol. 2011;18:3640-3649.
18. Reissfelder C, Rahbari NN, Koch M, et al. Postoperative course and clinical significance of biochemical blood tests following hepatic resection. Brit J Surg. 2011;98:836-844.
19. Burroughs AK. The hepatic artery, portal venous system and portal hyperten-sion: the hepatic veins and liver in circulatory failure. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, eds. Sherlock's diseases of the liver and biliary system. 12th, Oxford, UK: Wiley-Blackwell; 2011.
20. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897-6904.
21. Steinert G, Scholch S, Niemietz T, et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res. 2014;74:1694-1704.
22. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
23. Todaro M, Gaggianesi M, Catalano V, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14:342-356.
24. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271-285.
25. Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counter-balanced by CD47. Sci Transl Med. 2010;2:63ra94.
26. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 2009;119:1417-1419.
27. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-1428.
28. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-890.
29. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250: 440-448.
30. Poston GJ, Figueras J, Giuliante F, et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol. 2008;26:4828-4833.
31. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecu-tive cases. Ann Surg. 1999;230:309-318.
32. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver.Aprognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254-1262.
33. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125-135.
34. Reissfelder C, Rahbari NN, Koch M, et al. Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver meta-stases. Ann Surg Oncol. 2009;16:3279-3288.
35. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26:4906-4911.
36. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised con-trolled trial. Lancet. 2008;371:1007-1016.
37. Luzzi KJ, MacDonald IC, Schmidt EE, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153:865-873.
38. Cameron MD, Schmidt EE, Kerkvliet N, et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 2000;60:2541-2546.
39. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol. 1973;242:148-149.
40. Colombano SP, Reese PA. The cascade theory of metastatic spread: are there generalizing sites? Cancer. 1980;46:2312-2314.
41. Bross ID, Viadana E, Pickren J. Do generalized metastases occur directly from the primary? J Chronic Dis. 1975;28:149-159.
42. Weiss L, Grundmann E, Torhorst J, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150: 195-203.
43. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213-3221.
44. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med. 2013;91:431-437.
45. Diaz Jr LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579-586.
46. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014;6:224.
47. Weitz J, Koch M, Kienle P, et al. Detection of hematogenic tumor cell dissemination in patients undergoing resection of liver metastases of color-ectal cancer. Ann Surg. 2000;232:66-72.
48. Koch M, Kienle P, Hinz U, et al. Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg. 2005;241:199-205.
49. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232-239.
50. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-231.
51. Sennino B, Ishiguro-Oonuma T, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012;2:270-287.
52. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med. 2004;350:2335-2342.
53. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381: 303-312.